Welcome to BioSeeker Group!

Triple Analysis: Prostate Cancer, Apoptosis and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4123
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Prostate Cancer, Apoptosis and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Prostate Cancer, Apoptosis and Peptides.

    To find out more about Triple Analysis: Prostate Cancer, Apoptosis and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Prostate Cancer, Apoptosis and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

Part II: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

Part II: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
7TM Pharma
Abbott
Acceleron Pharma
Access
Active Biotech
Advanced Life Sciences
Advantagene
AEgera
AEterna Zentaris
Affymax
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alchemia
Alethia Biotherapeutics
Allos Therapeutics
Allostera
Allosterix
Alnylam
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambrilia Biopharma
American Gene Technology International
Amgen
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
Anchor Therapeutics
AndroBioSys
AngioChem
Angstrom Pharmaceuticals
Antisense Pharma
Antisense Therapeutics
Antisoma
Aphios
AplaGen Biopharmaceuticals
Apogenix
ApopLogic Pharmaceuticals
Apotex
Aprea
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVI BioPharma
Avila Therapeutics
Basilea Pharmaceutica
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
BioAlliance Pharma
BioAxone
Biocad
Bioenvision
Biogen Idec
BioInvent
Biokine Therapeutics
BioLineRx
BioMarin
Biomas
BioNetWorks
Bionovo
BioSante
Biostar
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Cel-Sci
Celecure
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celsion
Center of Molecular Immunology
Cephalon
ChemoCentryx
Chemokine Therapeutics
Chiasma
Chlorogen
Chroma Therapeutics
Circadian Technologies
Cleveland BioLabs
Clinuvel
Colby
CombinatoRx
Compugen
Coronado Biosciences
Cosmo Bioscience
Critical Outcome Technologies
Curaxis
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Dendreon
DeveloGen
Digna Biotech
Dongkook Pharm
ECI
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Endocyte
Enkam Pharmaceuticals
Ensemble Discovery
EntreMed
EpiCept
Erimos
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
Ferring
Formula Pharmaceuticals
Galena Biopharma
Gemin X Pharmaceuticals
Generex
GENova Biotherapeutics
Genovax
Genta
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
Glycotope
Got-a-Gene
GP Pharm
GPC Biotech
Green Cross
Gryphon Therapeutics
GTx
Harbor BioSciences
Hoffmann-La Roche
Human Genome Sciences
Idera Pharmaceuticals
IGF Oncology
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunotope
ImmuPharma
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intradigm
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Ivy Medical Chemicals
Johnson & Johnson
KAEL-GemVax
Kalypsys
Karo Bio
Karyon-CTT
Keryx Biopharmaceuticals
Kinex
Kirax
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
Ligand
Lorus Therapeutics
Mannkind
Marillion Pharmaceuticals
MBiotec
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Medivation
Menarini
Merck & Co
Merck KGaA
Merrion Pharmaceuticals
MethylGene
Mojave Therapeutics
Molecular Insight
MolMed
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
Neurocrine Biosciences
Nidus Laboratories
NIH
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
Novelix
Novogen
NPS Pharmaceuticals
Oasmia
OncoGenex Pharmaceuticals
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Pantarhei Bioscience
Patrys
Pepscan Therapeutics
Peptagen
PepTx
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
Pierre Fabre
Progen
Progenics Pharmaceuticals
ProMetic Life Sciences
ProNAi Therapeutics
ProStrakan
Protagonist
Q Chip
QLT
Raptor Pharmaceutical
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Rexahn
Rigel
Rosetta Genomics
Salzburg Therapeutics
Samyang
Sanofi
Santaris Pharma
Sapphire Therapeutics
Sarepta Therapeutics
SBI Biotech
SBIO
SciClone Pharmaceuticals
Seattle Genetics
SeleXel
Semafore Pharmaceuticals
Senesco Technologies
Serometrix
SGX Pharmaceuticals
Shire
Siena Biotech
Sigma-Tau
Soligenix
Sophiris Bio
Spectrum Pharmaceuticals
SRI International
SuperGen
Supratek Pharma
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Tapestry Pharmaceuticals
Tau Therapeutics
Taxolog
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Tigris Pharmaceuticals
Titan Pharmaceuticals
Tokai Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Transgene
Twinstrand Therapeutics
UMN Pharma
Unigene
United Biomedical
ValiRx
Vaxil BioTherapeutics
Vaxon Biotech
VBL Therapeutics
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viragen
Viralytics
ViroTarg
VM Discovery
Xerion
Xigen
Xoma
YM BioSciences
Zelos Therapeutics
Zensun
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abarelix
abiraterone acetate
ABT-510
adecatumumab
aderbasib
AEG-35156
AEZS-108
afamelanotide
afatinib
aflibercept
ALT-801
alvocidib
AME-133
amonafide dihydrochloride
amonafide malate
angiopep+paclitaxel
APC-100
APG-101
APR-246
ARC-100
ARQ-197
AS-101
AS-1411
atrasentan
AVX-701
bafetinib
bardoxolone methyl
belinostat
bevacizumab
BIBF-1120
bicalutamide
BMS-777607
BMS-936558
bortezomib
bosutinib
BP-GMAX-CD1
buserelin
BZL-101
Cabozantinib
canfosfamide hydrochloride
carlumab
CBP-501
cediranib
celecoxib
cenersen
cetuximab
cintredekin besudotox
cixutumumab
conatumumab
corticorelin acetate
crolibulin
custirsen
danusertib
dasatinib
DCVax-prostate
degarelix
denosumab
deslorelin
DI-17E6
dinaciclib
docetaxel
dovitinib lactate
doxercalciferol
doxorubicin
dulanermin
dutasteride
E-75
emepepimut-S
entinostat
enzastaurin hydrochloride
EP-100
estramustine phosphate sodium
ethinyl estradiol sulfonate
everolimus
figitumumab
flutamide
fosbretabulin tromethamine
FPI-01
fulvestrant
gataparsen
GDC-0980
gefitinib
goserelin
GT-111
GTx-758
GV-1001
GVAX
GVX-3322
GX-301
HE-3235
Her-2/Neu peptides
histrelin
ibritumomab tiuxetan
idronoxil
imatinib mesilate
imetelstat
imMucin
inecalcitol
INSM-18
interleukins
intetumumab
ipilimumab
IPP-204106
irosustat
ISA-P53-01
ispinesib mesylate
kahalalide F
KX2-391
lanreotide
lapatinib ditosylate
lestaurtinib
leucine-doxorubicin
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
leuprorelin acetate
LIP-131I
LipoVIL12
litronesib
lonaprisan
LOR-2040
LOR-2501
lumiliximab
LY-2275796
mapatumumab
MCS-110
MDV-3100
MDX-1379
MKC-1
MLN-8237
mocetinostat
motexafin gadolinium
Nab-docetaxel
nadroparin
NAFB001
navitoclax
netupitant
nilutamide
nimotuzumab
noscapine
obinutuzumab
oblimersen sodium
octreotide
octreotide, LAR
OGX-427
olaparib
olaratumab
ON-01910
Oncohist
orteronel
OTS-102
ozarelix
paclitaxel
paclitaxel polyglumex
panitumumab
panobinostat
pasireotide
pasireotide LAR
PAT-SC1
PBI-1402
PCI-24781
perifosine
pertuzumab
plitidepsin
PLX-3397
polyclonal antibody stimulator
ProstAtak
PROSTVAC
PRX-302
PX-12
PX-866
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
ramucirumab
retaspimycin
ridaforolimus
rilotumumab
rindopepimut
romidepsin
romurtide
ruxolitinib
sagopilone
sargramostim
SB-939
seliciclib
siltuximab
sipuleucel-T
sorafenib tosylate
sotatercept
SPC-2996
ß-lapachone
SU-6668
Survivac
TAK-448
tandutinib
tasquinimod
temsirolimus
Tenarad
terameprocol
thymalfasin
tigapotide triflutate
tigatuzumab
tipifarnib
TL-32711
TM-30339
TOK-001
toremifene citrate
TRC-105
tremelimumab
triciribine phosphate
trilostane
triptorelin
TroVax
TRU-016
TS-1
tucotuzumab celmoleukin
vandetanib
vapreotide, immediate-release
vitespen
volasertib
vosaroxin
VX-001
XL-147
XL-647
YM-155
zibotentan

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Prostate Cancer, Apoptosis and Peptides.
    To find out more about Triple Analysis: Prostate Cancer, Apoptosis and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Prostate Cancer, Apoptosis and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Leukemia, Melanoma and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Cancer Vaccines. Learn More


Triple Analysis: Melanoma, Prostate Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the compound strategy of Antibodies. Learn More

Other selected research from the 'Oncology' category:


Competitive Outlook on Non-Antibody Based Cancer Vaccines
Research and development in the cancer vaccine field is dominated by its top 10 players, interestingly not including any of the big pharma companies per se. The recent Gardasil approval and GlaxoSmithKline’s acquisition of Corixa will certainly push the industry towards more acquisitions. With this in mind, this report makes an in-depth assessment of competitive landscape, tumor antigen technologies, immunostimulatory strategies, vaccine delivery technologies, and a progress analysis of six major cancer vaccine indications. Learn More


Target Atlas in Pancreatic Cancer: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More